ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RCEL vs CERS // 10Y YIELD & FRED MACRO BETA

Avita Medical Inc. (NASDAQ) VS. Cerus Corporation (NASDAQ) • 15-METRIC TALLY: RCEL 2 — CERS 6
■ METRIC PARITY
macro-sensitivity
—
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RCEL VS. CERS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RCEL CERS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 82.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -15.50% -19.50 CERS /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.23% 0.23% -6.46 CERS /fcf-yield <GO>
Operating Margin -59.40% -3.70% -55.70 CERS /operating-margins <GO>
Net Profit Margin -60.00% -6.70% -53.30 CERS /net-margins <GO>
Revenue Growth (YoY) 11.50% 16.10% -4.60 CERS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 6/9 -2.00 CERS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.1 44.7 +16.40 RCEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $484.0M $459.5M $24.5M RCEL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RCEL REV CERS REV RCEL GROSS % CERS GROSS % RCEL FCF CERS FCF
FY 2025 $71.6M $233.8M 82.1% — -$32.2M $1.1M
FY 2024 $64.3M $201.3M 85.8% — -$58.1M $8.5M
FY 2023 $50.1M $186.8M — — -$38.0M -$43.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RCEL // BETA —
CERS // BETA —